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Abstract
Ramshur, John Thomas. M.S. The University of Memphis. August/2010. Design,
Evaluation, and Application of Heart Rate Variability Software (HRVAS). Major
Professor: Amy L. de Jongh Curry, Ph.D.
The analysis of heart rate variability (HRV) has become an increasingly popular and
important tool for studying many disease pathologies in the past twenty years. HRV
analyses are methods used to non-invasively quantify variability within heart rate.
Purposes of this study were to design, evaluate, and apply an easy to use and open-source
HRV analysis software package (HRVAS). HRVAS implements four major categories of
HRV techniques: statistical and time-domain analysis, frequency-domain analysis,
nonlinear analysis, and time-frequency analysis. Software evaluations were accomplished
by performing HRV analysis on simulated and public congestive heart failure (CHF)
data. Application of HRVAS included studying the effects of hyperaldosteronism on
HRV in rats. Simulation and CHF results demonstrated that HRVAS was a dependable
HRV analysis tool. Results from the rat hyperaldosteronism model showed that 5 of 26
HRV measures were statistically significant (p<0.05). HRVAS provides a useful tool for
HRV analysis to researchers.
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Introduction
The analysis of heart rate variability (HRV) has become a standard tool for studying a

wide variety of clinical and research topics. These areas have ranged from autonomic
nervous system (ANS) regulation, risk stratification for sudden cardiac death, diabetic
neuropathy, pharmaceutical evaluations, to psychological disorders [1-5]. Heart rate
variability, in its simplest form, is the variation in time between consecutive heart beats.
HRV analysis attempts to non-invasively quantify these variations which in some
instances can be markers of pathophysiology. Heart rate (HR), like many physiological
set points, e.g., blood pressure and temperature, is not a static parameter, but rather
changes within a range in reaction to bodily demands. Healthy cardiovascular systems
are ready to quickly detect and respond to changing needs placed upon the system in
order to restore homeostasis and permit directed activities. Conversely, it is often shown
that invariant HR is linked to disease systems such as heart failure [2, 6]. HRV provides a
means to assess overall cardiac health and its regulating system.

1.1 Background
In 1963 Hon and Lee were among the first to show the clinical significance of HRV
by noting that changes in interbeat intervals (IBI) preceded both fetal distress and
changes in overall heart rate [7]. In the late 1960’s and early 1980’s others began to
describe physiological rhythms contained within the beat-to-beat HR signal [8-10]. A 10year study relating short-term IBI differences to autonomic neuropathy was published in
1985 by Ewing et al. [11]. Wolf et al. contributed substantially to the HRV community in
1977 by showing an association between higher mortality risks after myocardial
1

infarction and reduced HRV [12]. Again during the 1980’s HRV was established as a
“strong and independent predictor” for post-infarction mortality [13-15]. The decades of
1970 and 1980 also produced strong evidence relating reduced HRV to severity of
diabetic autonomic neuropathy [16, 17].
The increasing availability and computational power of personal computers have
contributed much to the increase in HRV analysis. In 1981, a signal analysis tool for
quantifying spectral components of a time series was applied to HR fluctuations by
Akselrod et al [18]. From the 1990’s to present there has been a greater effort to describe
HRV as a nonlinear signal, and not just combinations of periodic oscillations [19-26].

1.2 Physiological Origins of HRV
In the absence of any outside influences spontaneous and periodic activation of the
pacemaker cells within the sinoatrial (SA) node determines the intrinsic heart rate. Action
potentials from the SA node spread throughout the atria to the atrioventricular (AV) node.
The AV node provides a propagation delay that allows for complete atrial depolarization
before action potentials propagate through the bundle of His, Purkinje fibers, and
ultimately throughout the ventricles.
Modulation of this inherent HR is accomplished by autonomic nervous system
innervations, the intrinsic cardiac nervous system, reflexes, respiration, and humeral
inputs. These modulating mechanisms not only act on the SA node but also on the
atrioventrical (AV) node, myocytes, conduction pathways, and both coronary and
peripheral vasculature. Correspondingly, cardiac chronotropism (heart rate), inotropism
(contractility), dromotropism (conduction), and vascular dilation/contraction are adjusted
to meet the dynamic cardiovascular demands of the body. The ultimate goal of the
2

cardiovascular system is to sustain and associated level of arterial blood pressure to
ensure sufficient organ perfusion.

1.2.1

Parasympathetic Nervous System

Efferent nerve fibers of the parasympathetic nervous system (PNS) originate in
collections of neurons in the dorsal vagal nucleus and the nucleus ambiguous of the
medulla. From the medulla PNS neurons descend to cardiac tissues via the tenth cranial
nerve (vagus) to a series of ganglia in and near the heart. Postsynaptic PNS neurons
innervate the SA node, AV node, myocytes, conduction pathways, and coronary
vasculature of the heart. The left vagal nerve primarily innervates the AV node while the
right vagal nerve innervates the SA node. However, there is some crossover between the
two.
Effects of PNS activation on the cardiovascular system are mediated by the
neurotransmitter acetylcholine. Acetylcholine (ACh) binds to postsynaptic M2 muscarinic
receptors in both cardiac tissue and vessels. Acetylcholine decreases inotropy,
chronotropy, and dromotropy in the heart and causes vasodilation in vessels including
coronary arteries.

1.2.2

Sympathetic Nervous System

Efferent sympathetic nervous system (SNS) nerve fibers descend from centers in the
medulla through the spinal cord and exit at the T1-L2 dorsal roots. Presynaptic neurons
synapse with postganglionic neurons of paravertebral ganglia. These postganglionic
neurons innervate the SA node, AV node, conduction system, myocytes, coronary
vasculature, and other vessels.
3

Sympathetic neurons release the neurotransmitter norepinephrine (NE) which binds to
postsynaptic β1, β2, and α1 adrenergic receptors on the heart with a higher affinity for β1.
These receptors increase chronotropy, dromotropy, and inotropy. NE also binds to
presynaptic α2-adrenoceptors at the heart and acts as a negative feedback loop that
reduced NE release.
At vessels, NE binds to postsynaptic α2 and α1-adrenoceptors to produce
vasoconstriction and binds to β2-adrenoceptors to produce vasodilation. As with cardiac
tissue, presynaptic binding of NE to α2-adrenoceptors in vessels produces a negative
feedback reducing NE release. NE also binds to presynaptic β2 receptors, but produces a
positive feedback of NE release. “Overall effects of sympathetic activation are to increase
cardiac output, systemic vascular resistance (both arteries and veins), and arterial blood
pressure” [27].

1.2.3

Intrinsic Cardiac Nervous System

Traditionally the ANS was thought to be the only nervous system directly associated
with HR modulating capabilities. However, recent evidence has shown that there is an
intrinsic cardiac network (ICN) capable of mediating intracardiac reflexes. In addition to
the classically described parasympathetic postganglionic neurons, the ICN includes
sensor neurons, interneurons, and catecholaminergic neurons [28]. “Thus, neural control
of HR is likely a function of both the intrinsic cardiac and autonomic nervous system”
[28].

4

1.2.4

Reflex Control

The previous few sections primarily discussed efferent pathways and mechanism for
modulating HR and other cardiovascular significant events. Cardiovascular control, as
with most physiological control systems, is not a simple feed-forward control system.
Autonomic feedback loops or feedback reflexes exist to allow hemodynamic
homeostasis. Receptor types involved in reflex control can include pressure, stretch,
chemical, pain, and thermal receptors.
Reflexes involved in autonomic control of HR are many, e.g., baroreceptor,
Baingridge, Cushing, pain, diving, and temperature reflex. The most often described
reflex associated with HR, in context to HRV, is the baroreceptor reflex or baroreflex
[29-31]. Baroreceptors located in the aortic arch and carotid sinus synapse with neurons
that project superiorly to the brainstem. The aortic arch is innervated by afferent neurons
from the aortic nerve which combines with other afferent neurons in the vagus nerve.
Afferent neurons innervating the carotid sinus receptors connect to the brainstem using
the glossopharyngeal nerve (cranial nerve IX). Both groups of afferent neurons synapse
with interneurons of the nucleus tractus solitaries (NTS) within the brainstem and
modulate the activity of both the PSN and SNS. Excitatory interneurons from the NTS,
which normally are excited by tonic baroreceptor activity, stimulate vagal activity and
inhibit sympathetic activity. Connections also exist between the NTS and hypothalamus.
To illustrate how the baroreflex works, consider the course of events that occur in
response to a person moving from supine to standing. Gravity simultaneously causes
blood to pool in the venous system and decreases venous return, which results in lower
central venous pressure, ventricular preload, and thus decreased arterial blood pressure.

5

Reduced arterial pressure results in less baroreceptor firing. The NTS responds by
reducing parasympathetic outflow and un-inhibiting (increasing) sympathetic outflow.
These ANS changes produce increases in chronotropy, inotropy, and vascular resistance.
The inability of the body to react in this manner would result in syncope (fainting).
Other types of reflexes incorporate chemical sensitive receptors. These
chemoreceptors are typically sensitive to partial pressures of O2 (pO2), CO2 (pCO2), and
to pH. Peripheral chemoreceptors within the carotid and aortic bodies, like the
baroreceptors, project to the medulla via the sinus (then the glossopharyngeal) nerve and
the vagus nerve respectively. Peripheral chemoreceptors increase firing in response to
reduced arterial pO2 (hypoxemia), increased pCO2 (hypercapnia), and increased pH
(acidosis). Central chemoreceptors located in the medulla regions that control
cardiovascular and respiratory activity respond similarly, but not directly in response to
hypoxia.

1.2.5

Respiratory Sinus Arrhythmia

Another type of reflex often mentioned in HRV literature is the respiratory sinus
arrhythmia (RSA) [32]. RSA is a cyclic modulation in the HR correlated with respiration.
Vagal afferent nerves in the lungs are excited during inhalation due to distention. The
result is similar to the increased baroreceptor firing of the baroreflex. Increase afferent
vagal activity during inhalation produces lowered vagal efferent activity and increased
sympathetic activity, thereby increasing HR. The opposite is true for expiration.

6

1.2.6

Humoral Control

Lastly there exist means of modulating HR (directly and indirectly) by circulating and
localized release of humoral substances. Indirect effects on the heart and vessels come
from changes in blood volume. One set of humoral substances are the circulating
catecholamines released from the adrenal medulla and sympathetic nerves that innervate
blood vessels. The adrenal medulla primarily releases epinephrine, and sympathetic
nerves primarily release norepinephrine. Both of these releases causes increase in HR,
however, other reflex controls may secondarily lead to a decrease [27]. Natriuretic
peptides, arginine vasopressin, nitric oxide, neuropeptides Y, and factors related to the
renin-angiotensin-aldosterone system (see Chapter 5) also contribute to changes in HR
[27, 33].

1.2.7

ANS Components of HRV

HRV studies describe distinct oscillations contained in IBI time series linked to
autonomic influences of HR [34-38]. With the use of computer analysis and
pharmacological studies, two primary HR oscillations have been defined. The high
frequency (HF) oscillation is often associated with the RSA and has nominal range of
0.15-0.4 Hz [39]. Because RSA is regarded as being mediated by vagus activity, the HF
oscillation is often denoted as a measure of vagal activity [40]. The other primary HR
oscillation described in HRV is the low frequency (LF) oscillation existing between 0.040.15 Hz [39]. This band includes the 10 second rhythm or Mayer wave [41]. Some
controversy exists on whether only sympathetic activity is represented in the LF
oscillation, but most consider LF a combination of sympathetic and vagal activity [40].
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To validate the aforementioned HR oscillations, both electrophysiological and
pharmacological studies have been performed on the SNS and PNS [34, 35, 37, 42].
Selectively blocking or stimulating sympathetic activity, vagal activity, or both provided
a means to link frequency bands with the ANS branches. Specifically, an antagonist for
the muscarinic acetylcholine receptors, atropine, was used in vagal blockades, while betaadrenergic antagonists such as propranolol were used for sympathetic blockade.
These studies further revealed that the vagal mediated changes of HR are faster than
sympathetically mediated changes [40]. The primary reason for differences of response
rates is attributed to the receptor processes and postsynaptic responses. It was
demonstrated that the majority of molecules involved in muscarinic binding processes are
mostly located within the cell membrane [43]. Conversely, adrenergic receptor binding
processes involve secondary messaging pathways before membrane ion channel changes
and thus causing a longer response time [43].
In addition to LF and HF oscillations, two lesser described HR oscillations exist
below 0.04 Hz. The very low frequency oscillation (VLF; 0.003-0.05 Hz) and ultra low
frequency oscillation (ULF; below 0.003 Hz) have been studied less than the preceding
two bands. Thermoregulatory cycles and fluctuations of plasma renin activity may
contribute to VLF [44-46]. Circadian rhythms are typically the acknowledged primary
contributor to the ULF frequency band [40, 44]. These two oscillations, particularly ULF,
are often contaminated with low frequency trends resulting from possible intrinsic nonstationarities of IBI signals [47].
The above descriptions of physiological mechanisms that affect HR are by no means
an exhaustive list. Heart rate is controlled by many feed-back and feed-forward systems
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that are directly and/or indirectly integrated together. The complex interplay of these
systems leads to variations in HR that are used in HRV analysis.

1.3 Justification and Purpose of Research
HRV analysis has become a widespread tool used by researchers and clinicians and
the interest is continuing to increase. A literature search in the National Library of
Medicine’s Medline database show that more than 1,000 HRV articles were published in
2009, over 4,000 in the last 5 years, and a two fold increase in HRV publication per year
compared to 10 years ago. Interest has increase to the point that commercial HRV
software is now available for clinicians to aid in cardiovascular disease diagnosis, and for
continuous monitoring. Disease classification, treatment planning, progress monitoring,
and outcome predicting are primary goals in health care that generate much interest with
HRV.
Though the use of HRV is prevalent, there is a continuing need for software packages
that include updated and validated HRV analysis methods in an easy to use platform for
both researchers and clinicians. Because any novel techniques and some current
techniques can produce obscure results, there is a need for interpretive methods to give
physiological meaning to HRV analysis particularly for clinicians. Another need in HRV
analysis is to standardize analysis techniques and to characterize HRV measures for
specific populations of pathophysiology such as heart failure and models of induced heart
failure such as hyperaldosteronism.
The purposes of this study are three fold: (1) Design a HRV analysis software
package with the intended consequence of developing an understanding of techniques
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used in HRV analysis, (2) evaluate the software using simulated and public data, and (3)
apply the software by studying the effects of hyperaldosteronism on HRV in rats.

1.4 Thesis Guide
Chapter 2 introduces several techniques used in HRV analysis. Each of these
techniques was implemented within the Heart Rate Variability Analysis Software
(HRVAS). Chapter 3 describes specific design elements of HRVAS. Chapter 4 discusses
two evaluations that were performed to validate HRVAS. Chapter 5 discusses the
application of HRVAS to study hyperaldosteronism in rats. Finally, Chapter 6 includes an
overall summary of the research presented.
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2

HRV Analysis
This chapter describes several analysis methods used in HRV. The first section

describes techniques used to process IBI time series prior to HRV analysis. The
remaining four sections describe four major categories of HRV analysis. These four
major categories include: time based metrics (e.g., variance); frequency based metrics
that evaluate powers or ratios of powers within certain frequency bands; nonlinear based
metrics that evaluate complexity and self-similarity; and time-frequency metrics that
expand on frequency based metrics by monitoring them through time. For alternative
overviews of HRV analysis see articles by Seely et al. [48], Acharya et al. [49], Berntson
et al. [40], and Malik et al. [39].

2.1 IBI Extraction
Data series used in HRV analysis are time series containing beat-to-beat intervals
extracted from ECG signals. Temporal locations of beats are frequently based on the Rwave because it is often the easiest wave to distinguish. R waves typically have the
largest amplitudes compared to surrounding P, Q, S, and T waveforms. Thus a beat-tobeat interval can be defined as the time difference between consecutive R peaks (RR
interval). Because the R wave is not the only temporal marker for beat locations, e.g.,
QRS complex, some use the term IBI as a generalization to represent any beat-to-beat
intervals. Additionally, RR intervals originating from normal sinus rhythms are
sometimes referred to as NN (normal-to-normal) intervals. Thus, standard nomenclature
of “NN” is used in place of IBI or RR to indicate IBI’s containing no ectopic intervals.
Many authors, including this research, interchangeably use IBI, RR, or NN (normal-tonormal) to represent IBI series assuming ectopic beats have been corrected.
11

Fig. 1 shows a hypothetical ECG and how IBI’s are determined based on R waves.
IBI(1) and IBI (2) represent the first and second data point of the IBI time series signal.
The IBI time series of an ECG segment containing N beats is given by
IBI  n   beat  n  1  beat (n) :1  n  N  1

(2.1)

where beat(n) is the time location of the nth beat.

Fig. 1 – Determination of IBI. Simulated ECG containing three beats with arbitrary units
of time and amplitude. Time intervals corresponding to the IBI are indicated by IBI(1)
and IBI(2). ECG morphology is shown by five characteristic waves P, Q, R, S, and T.

2.2 Preprocessing
Preprocessing of IBI time series data is frequently required before HRV analysis to
reduce analysis errors. The three primary types of IBI preprocessing are ectopic
12

beat/interval correction, detrending, and IBI resampling. HRV analysis errors due to
ectopic beats and IBI trends have been reported by Thuraisingham [50] and Colak [51].
In the context of IBI, ectopic beats refer to any IBI based on one or more abnormal beats.
Any abnormal IBI due to a false/missed beat, fiducial point misalignment, or cardiac
ectopy may be considered ectopic.
IBI time series also contain slowly varying trends that are generally assumed to be
inherent to most biological signals including IBI. Some HRV analysis methods assume
that IBI signals are stationary or absent of low frequency trends. Specifically, power
spectrum estimations based on Fourier transform require that the random variable of
interest be wide sense stationary (the mean does not change with time) [52]. To alleviate
any non-stationarities within IBI time series, detrending is often used before HRV
analysis [51, 53, 54]. In addition to stationarity, these methods require evenly sampled
IBI, which is inherently not the case for IBI signals. Fig. 2 illustrates an IBI time series
before and after removing both ectopic intervals and low frequency trend.
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Fig. 2 – IBI signal before and after detrending and ectopic interval removal. IBI time
series from healthy human.

2.2.1

Ectopic Interval Detection

Before ectopic intervals can be corrected they must first be detected or marked. Here
three detection techniques are discussed. Although the term filter is used in this section,
no change to the original IBI occurs during ectopic interval detection. The percentage
filter locates intervals that change by more than a user defined percentage (often 20%)
from the previous interval [55]. This method locates any sudden or abrupt IBI changes.
Another method used to detect ectopic intervals is the standard deviation filter which
marks outliers as being intervals that lie beyond the overall mean IBI by a user defined
value of standard deviations (often 3 SD) [55]. Lastly, the median filter acts as an
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impulse rejection filter with threshold to delineate ectopic intervals [50]. The median
filter of a random variable x of length N using a threshold of τ is given by
D ( n) 

x  n   med ( x)



1.483  med x  n   med ( x)



(2.2)

if D  n    , then not ectopic; else ectopic

2.2.2

Ectopic Interval Correction

Four correction techniques are described to replace ectopic intervals found during the
detection process. The first technique is to simply remove any ectopic intervals found.
Simple ectopic interval removal has been shown to be as effective as other replacement
methods [56]. Another method replaces any ectopic interval with the mean value of w
neighboring IBI intervals centered on the ectopic interval using Equation (2.3) .
Similarly, the median method replaces ectopic intervals with the median value of w
neighboring IBI intervals centered on the ectopic interval using Equation (2.4) [50].
Lastly, cubic spline replacement replaces ectopic intervals using cubic spline
interpolation.

2.2.3

w  1

ibi '  n   mean ibi  n  m  : m 

2 


(2.3)

w  1

ibi '  n   med ibi  n  m  : m 

2 


(2.4)

IBI Detrending

Several methods of detrending exist in the literature to remove low frequency trends
including: linear detrending, polynomial detrending, wavelet detrending, wavelet packet
detrending, and smoothing priors detrending.
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2.2.3.1 Linear and Polynomial Detrending
Two of the simplest methods used for detrending IBI series are linear and polynomial
detrending [57-59]. Linear detrending is accomplished by removing a linear leastsquares-fit from the IBI series. Similarly, polynomial detrending removes a second or
third order polynomial fit (in a least squares sense) from the IBI series.

2.2.3.2 Wavelet Detrending
Wavelet detrending is accomplished by decomposing the original IBI time series into
a tree of approximation and detail coefficients using discrete wavelet transform (DWT)
(see Section 2.5.2.2). Each decomposed sub-band is associated with a range of
frequencies with the highest level of approximation containing the lowest frequencies.
Removing the low frequency trend can be accomplished by two methods. The first
method sets all the wavelet coefficients of the highest level approximation (lowest
frequency) to zero, and then performs an inverse DWT. The alternative method
reconstructs only the highest approximation sub-band which is then subtracted from the
original IBI series [50]. Either method effectively applies signal detrending.

2.2.3.3 Wavelet Packet Detrending
Detrending using wavelet packets works similar to the detrending method based on
DWT mentioned in the previous section. Instead of decomposing the signal using DWT
the discrete wavelet packet transform (DWPT) is used (see Section 2.5.2.2). Wavelet
coefficients of sub-bands that contain frequency components of any unwanted trend are
set to zero. Reconstruction of the IBI series using inverse DWPT produces a detrended
IBI series [60]. As before, an alternative detrending approach using DWPT is to
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decompose the signal, reconstruct any unwanted components, and subtract the unwanted
components from the original signal.

2.2.3.4 Smoothing Priors
The final detrending method to be discussed is the smoothing priors approach [60,
61]. In the smoothing priors approach a N-1 long, an equally sampled IBI time series is
represented as the combination of stationary and trend components, z  zstationary  ztrend .
This method computes a stationary signal from the original. The estimated stationary
component is written as





1
zˆstationary  z  Hθˆ   I   I   2 DT2 D2  z

where H  R

N 1 xM

(2.5)

is the observation matrix. For simplification, an identity matrix is

used in place of the observation matrix H . θˆ λ represents the estimate of the regression
parameters with  as the regularization parameter and D2  R N 3x N 1 is the second
order difference matrix.

2.2.4

IBI Resampling

In addition to most Fourier based power spectrum estimates (see Chapter 2.4)
requiring signal stationarity; they also require time series that are regularly sampled in
time. Spectrum estimates taken from irregularly time sampled signals can introduce
additional harmonics into the power spectrum [62]. For this reason, IBI time series must
be resampled prior to some power spectrum estimates. Commonly used resampling
schemes are cubic spline and linear interpolation [63].
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2.3 Time-Domain Analysis

2.3.1

Statistical Measures

Time domain HRV analyses are often classified as statistical or geometric methods.
Statistical time-domain measures are statistical based measures calculated directly from
the IBI series. Time domain measures include: mean IBI, the standard deviation of the
NN interval series (SDNN), the root mean square of successive differences of the IBI
series (RMSSD), the number of successive differences that are greater than x
milliseconds (NNx), and the percentage of total intervals that successively differ by more
than x milliseconds (pNNx) [64].
Two variants of the SDNN are used with longer datasets. The first step in both of
these variations involves separating the IBI series into non-overlapping segments. For
human IBI’s the segment lengths are often five minutes [39]. The first variant is the
SDNN index or SDNNi, Equation (2.6) , and is computed by finding the standard
deviation of each IBI segment and then returning the mean value of standard deviations.
The SDANN measure is computed in the opposite manner, Equation (2.7). SDANN
computes the mean IBI of each segment and then returns the standard deviation of all
means. SDNNi and SDANN are represented mathematically using the following
equations:

SDANN 

1
M

M

 SDNN  i 

(2.6)

2
1 M
 meanIBI  i   meanIBI 


M  1 i 1 

(2.7)

SDNNi 
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i 1

where SDNN(i) represents the SDNN value of the ith IBI segment, meanIBI(i) represent
the mean IBI value of the ith IBI segment, and M is the total number of segments.

2.3.2

Geometric Measures

Geometric HRV measures are based on calculations taken from a geometric pattern
who’s basis lies with the IBI series [39]. The most common geometric pattern used is the
histogram of IBI. Two measures based on the IBI histogram are the HRV triangular index
(HRVti) and the triangular interpolation of the NN interval histogram (TINN). Fig. 3
represents the histogram of a hypothetical IBI series where D(t) is the density distribution
of IBI. The maximum value of D(t) is represented by Y and is located at t=X. HRVti is
the value obtained by dividing the area integral of D(t) by the maximum value Y. If the
distribution D(t) is on a discrete horizontal scale then the area integral is just the total
number of IBI intervals NIBI. Therefore HRVti is obtained by
HRVti 

N IBI
.
Y

(2.8)

For the computation of TINN the values N and M are established on the time axis and
a triangular function q(t) constructed such that q(t)=0 for M ≤ t ≤ N. The peak of the
triangle occurs at q(X)=Y. The triangle base defined by M and N are determined by


minimizing the integral  ( D(t )  q(t )) 2 dt . Finally, TINN is expressed in milliseconds
0

and computed using [39]
TINN  M  N .
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(2.9)

Fig. 3 – Histogram of hypothetical IBI time series. D(t) represents the sample
distribution. q(t) represents a triangular function fitted to D(t) by minimizing the integral
of the squared difference between D(t) and q(t). Y = D(X) = max(D).

2.4

Frequency-Domain Analysis
Fluctuations in HR are often thought to be periodic and occurring on many time

scales [65]. Quantifying these fluctuations within the IBI time series can be done by
calculating the power spectrum density (PSD). The PSD presents spectral power density
of a time series as a function of frequency. Therefore, PSD estimates can give
information about the amount of power in which certain frequencies contribute to a time
series.
In general, frequency-domain HRV analysis is concerned with four previously
mentioned frequency oscillations or bands [39]: ULF, VLF, LF, and HF. For humans
ULF, VLF, LF, and HF frequency bands are defined to be 0-0.0033 Hz, 0.003-0.04 Hz,
0.04-0.15 Hz, and 0.15-0.4 Hz respectively. The ULF and VLF are often ignored due to
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the lack of long data recordings needed to accurately resolve these frequencies or due to
the use of IBI detrending techniques that may destroy information within those bands.
Typical HRV measures taken from frequency-domain analysis are powers within
frequency bands and ratios of powers. The amount of power contained within a frequency
band is obtained by integrating the PSD between the band frequency limits. Measures of
spectral power are reported as absolute (aVLF, aLF, aHF), percentage of the sum of aLF
and aHF (pLF, pHF), or normalized to total power (nLF, nHF). In addition to the power
measures, the ratio of LF to HF (LFHF) provides a so called sympatho-vagal balance.
Finally, less commonly mentioned measures are the peak frequencies within the VLF,
LF, and HF bands.
Estimating the PSD can be performed using many methods, but methods based on
Fast-Fourier Transform (FFT) and autoregressive (AR) modeling are perhaps the most
popular in spectral analysis of HRV [65]. Classical power spectrum estimates developed
by Bartlett (1948), Blackman and Tukey (1958), and Welch (1967) are examples of
methods based on FFT [66]. Because the FFT makes no assumptions on how the data are
generated the classical methods are often referred to as non-parametric. The AR power
spectrum methods do make assumptions and are therefore called parametric. Contributing
to the popularity of the FFT based estimates are their simplicity, broad understanding,
and ease of computation using modern computers and software.
However, both FFT and AR based PSD estimates have prerequisites that are seldom
if ever met by biological signals such as cardiac IBI series [67]. Both methods require the
analyzed time signal to be stationary and evenly sampled, which is inherently not the case
with IBI signals [52, 66]. The commonly used linear and cubic spline resampling were
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shown to overestimate the LFHF ratio with an error that is greater than the error between
population differences [68]. Consequently, other methods such as the Lomb-Scargle
periodogram and methods based on wavelet transforms are becoming popular [32, 6973]. Lomb-Scargle does not require resampling and wavelet transform based estimates do
not require stationarity [74]. Despite the aforementioned limitations of FFT and AR
based PSD estimates, they are widely used in HRV.

2.4.1

Welch Periodogram

To understand Welch’s periodogram one must first understand the discrete Fourier
transform (DFT), the basic periodogram, and the modified periodogram. The N-point
DFT of a random variable X(n) is given by
N 1

DFTx ( f )   X  n  e

i 2 fn

(2.10)

n 0

Practical computations of the DFT use the FFT for speed advantages. The periodogram,
extension of the DFT, is a basic method of estimating power spectral density of a time
series and is given by

P

f 

1
N

N 1

 X  n e

i 2 fk / L

2
k=0,1,...,L-1.

(2.11)

n 0

Reducing spectral leakage of the periodogram can be accomplished by incorporating a
weighted windowing function w(n), e.g., Hamming and Hanning, to the input series. Data
near the edges of the time series are given less weight compared to data nearer the center.
Thus, the modified periodogram is given by

PM  f  

1
MU

M 1



X n w n e

n 0
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i 2 fn

2
i=0,1,...,L-1

(2.12)

M 1

where U  1/ M  w2  n  . Finally, in an effort to reduce the variance of the periodogram
n 0

estimation, the Welch method separates the data series into N overlapping segments. As
with the modified periodogram the Welch method applies a weighting window to reduce
spectral leakage, but weighting is applied to each segment. Finally an averaged PSD is
calculated using all segments. Power spectral density by the Welch periodogram is given
by
PW  f  

1
N

N 1

P  f 
i 0

(2.13)

M ,i

where PM ,i  f  is the ith modified periodogram from the data series.

2.4.2

Burg Periodogram

Autoregressive spectral estimation methods differ from non-parametric methods in
that they attempt to model the data instead of estimating the PSD directly. Several
modeling methods exist for AR spectrum estimation, but the Burg method is the most
common in HRV [49, 75, 76].
The power spectrum of a pth order autoregressive process is given by

PBurg  f  

1
fs

p
p

1   a p  k  e2 jkf / f s

2

(2.14)

k 1

where εp is the total least square error, fs is the sample rate, and a p are the Burg AR
model parameters [77]. Boardman, et al. suggests that a model order of p=16-20 is a
sound choice for HRV in human IBI resampled at 2-4 Hz [78].
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2.4.3

Lomb-Scargle Periodogram
As mentioned before the Lomb-Scargle periodogram (LSP) method of estimating

PSD does not require resampling. The LSP only uses available data. Conceptually LSP
estimates the frequency spectrum by performing a least squares fit of sinusoids to the
data. Unlike Welch’s periodogram weighted windowing functions are not applied to data
in LSP because standard weighting methods cannot be applied to unevenly sampled data.
The LSP of a non-uniformly sampled, real-valued data sequence X of length N for
arbitrary times tn is defined by
2
 N
 
   X  tn   X cos  2 f  tn      
 
  n 1
N


cos 2  2 f  tn    



1 

n 1
PLS ( f ) 

2 
2
2   N
 
   X  tn   X sin  2 f  tn      
 
  n 1
N


sin 2  2 f  tn    



n 1











(2.15)

where x and σ2 are the mean and variance of the time series, and



N

 

N



  tan 1    sin  4 ftn   /   cos  4 ftn    . τ is a frequency dependent time delay,
  n 1

  n 1



defined to make the periodogram insensitive to time shift[69-71]. A more detailed
description of the LSP appears in [70, 79]. Clifford et al. showed that ectopic beat
removal of up to 20% of the data points in an IBI signal does not introduce a
“significant” error in frequency-domain HRV measures based on LSP [68]. Because of
the resistance to errors from data removal and resampling, LSP could be the preferred
power spectrum estimation method for HRV. Comparison of the Welch, Burg, and
Lomb-Scargle (LS) periodograms are presented in Fig. 4.
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Fig. 4 – Comparison of PSD estimates. Estimates include (a) Welch periodogram, (b)
Burg autoregressive periodogram, and (c) Lomb-Scargle periodogram estimates. HRV
frequency bands are labeled as very low frequency (VLF, 0-0.04 Hz), low frequency
(LF, 0.04-0.15 Hz), and high frequency (HF, 0.15-0.4 Hz). PSD’s computed using
preprocessed IBI from healthy human. Powers represent percent of total power.

2.5 Time-Frequency Analysis
HRV analysis by means of frequency-domain methods can only yield information
about how IBI signal power is distributed in the frequency domain. They provide no
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insight into the temporal evolution of the spectrum. Methods used to allow simultaneous
viewing of both time and frequency information are often termed time-frequency
analyses. Like frequency-domain analysis, time-frequency HRV analysis quantifies VLF,
LF, and HF related measures. The two primary types of time-frequency analysis used are
the windowed Fourier transform (also called short-time Fourier transform, STFT) and the
continuous wavelet transform [80]. To include spectral estimation methods other than
the Fourier transform, the term windowed periodogram will be used in place of
windowed Fourier transform. This generalization allows the inclusion of the windowed
Burg periodogram and windowed Lomb-Scargle periodogram.

2.5.1

Windowed Periodogram

The windowed power spectrum is an extension of the basic PSD. As the term implies,
the data is broken down into consecutive (overlapping or not) segments or windows. The
PSD is then computed for each segment. This is similar to the technique use by Bartlett
and Welch. However, those methods lose any temporal information by averaging all
PSD’s into a single PSD. Unlike Welch’s method, the windowed periodogram can use
other techniques to compute the PSD, e.g. Burg periodogram. Plotting PSD values onto a
two-dimensional plane with frequency and time as the vertical and horizontal axes
respectively produces a spectrogram as seen in Fig. 5.
Two alternatives are the windowed Burg periodogram and the windowed LombScargle periodogram [81, 82]. For the windowed Burg periodogram the entire data series
is first resampled and then broken into segments of equal lengths. Finally, the PSD is
computed for each segment using the Burg periodogram.
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The windowed Lomb-Scargle periodogram is computed in almost the same manner.
First, the data is broken into segments of equal lengths of time [71]. Due to the uneven
sampling of IBI’s, each segment can contain differing number of data points. Finally, the
LSP for each segment is computed.
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Fig. 5 – Spectrogram and waterfall plot for windowed periodograms. Plots generated
using preprocessed IBI from healthy human. Plots include (a) Spectrogram using
windowed Bug periodogram. (b) Spectrogram using windowed LSP (c) Waterfall plot
containing Burg periodograms of each five minute segment of IBI.

HRV quantification from time-frequency analysis using windowed periodograms can
be accomplished two ways. The first method computes an averaged or global power
spectrum and then calculates typical frequency-domain HRV measures, e.g., LF, HF, and
LFHF. Averaging the power spectrum eliminates any time resolution and defeats some of
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the purpose of time-frequency analysis, but it provides a way to help control variances by
averaging many power spectrums [83]. Alternatively, HRV measures can be calculated
for each segment, and then an average HRV measure computed. The second method
produces discretely instantaneous frequency-domain measures that are a function of time,
e.g., LF(t) and LFHF(t).
From the LFHF instantaneous time series, another index can be extracted called the
ratio of LFHF ratios (rLFHF) [81]. This measure represents the “global” sympatheticparasympathetic equilibrium [81]. Imagine a line drawn through LFHF =1 on the
instantaneous LFHF plot. Above this line (LFHF >1) there is a sympathetic dominance.
Below this line (LFHF <1) there is a parasympathetic dominance. The rLFHF ratio is
obtained by calculating the ratio of the bounded area above the line LFHF=1 to the
bounded area below.

2.5.2

Wavelet Transforms

Wavelet transforms are a relatively recent, but enormously popular tool for analyzing
and compressing many types of time signals. The term wavelet implies a small wave and
is of finite length and energy [84]. Like Fourier transform the wavelet transform separates
a signal into its fundamental components. However, unlike the Fourier transform, wavelet
transforms can be applied to non-stationary signals and are not limited to a single set of
basis waveforms for signal decomposition. Fourier transforms rely on the sinusoid
waveform, whereas wavelet transforms have an infinite set of basis waveforms or mother
wavelets as long as they satisfy predefined mathematical criteria. This property may
provide access to information that could be obscured by methods like Fourier analysis
[85]. Acharya et al. state that “bio-signals usually exhibit self-similarity patterns in their
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distribution, and a wavelet which is akin to its fractal shape would yield the best results in
terms of clarity and distinction of patterns” [85].
The following summary of Acharya’s [49] understanding of wavelet transform
concepts provides an efficient explanation. The wavelet transform correlates a mother
wavelet with sections of the original signal to produce wavelet coefficients. The mother
wavelet is shifted/translated in time to generate a set of coefficients along the time signal.
Next the mother wavelet is contracted or dilated to create coefficients along the time
series at varying time scales. Here the term scale is analogous to frequency or more
precisely the pseudo frequency (average frequency). Scaled wavelets are normalized so
each one contains the same amount of energy. The scale can be thought of as the wavelet
width and the translation as its location in time. Larger scale values represent smaller
wavelet size and thus higher frequencies.
This research is concerned with the continuous wavelet transform (CWT), the discrete
wavelet transform (DWT), and discrete wavelet packet transform (DWPT). The major
differences between the three are how the wavelet function is scaled and translated.

2.5.2.1 Continuous Wavelet Transform
For a given signal x(t) and wavelet function  a ,b (t ) , the CWT coefficients are given by
W ( ,  ) 

1

 t 
x(t )  

 






dt


(2.16)

where   (t ) is the complex conjugate of the mother wavelet  (t ) , α is the dilation
parameter, and τ is the location parameter. The bivariant function W(τ,α) shows the
similarity of x(t) to a wavelet scaled by α at a given time τ [65]. Theoretically the CWT
wavelet coefficients are calculated for infinitesimally small translations and scale factors.
30

However, practical implementations of the CWT must balance the number of translations
and scales to produce acceptable computational times. Most programmatic
implementations of the CWT allow the user to specify the number of scales to use for
computation. Plotting CWT coefficients onto a two-dimensional plane with scale and
location as the vertical and horizontal axes produces a scalogram as seen in Fig. 6.

Fig. 6 – CWT scalogram of IBI data. CWT computed using preprocessed IBI from
healthy human with DOG2 wavelet [86]. The frequency axis is displayed using a log
scale and represents the equivalent frequency of CWT scales [86].

2.5.2.2 Discrete Wavelet Transform
In the case of DWT and DWPT, the scaling and translations are done in a less smooth
or more discrete manner. Scaling and translating for the DWT are based on powers of 2
or dyadic blocks, e.g., 21, 22, etc. The dilation function is often represented as a tree of
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low and high pass filters. The first step of the tree decomposes the original signal into
detail (high frequency) and approximation (low frequency) components. Detail and
approximation components for three levels of decomposition are represented in Fig. 7-a
by A and D. Only the approximations are further split into finer components in the DWT.
For DWPT both branches of the tree are split into finer components. Fig. 7-b shows the
tree for DWPT for 3 levels of decomposition.
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(a) DWT Decompositon
Original Signal

Level 1

A1

Level 2

A2

Level 3

A3

0

Scale 21

D1

Scale 22

D2

Scale 23

D3

0.125

0.25

0.5

1.0

Frequency (fraction of Nyquist)

(b) DWPT Decompositon
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Fig. 7 – DWT decomposition tree. Decomposition trees showing the breakdown of an
arbitrary original signal into three levels using (a) discrete wavelet transform and (b)
wavelet packet transform. Horizontal axis shows frequency range as a fraction of the
Nyquist frequency. DWPT can extract all frequency bands with equal resolution.
Diagram modified from Tanaka and Hargens [87].

Quantification of HRV measures from time-frequency analysis by CWT is
accomplished in a similar manner to that employed for the windowed periodogram.
Similar in that both can use either the instantaneous or global power spectrums [88]. To
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obtain HRV measures using instantaneous power methods, the squared modulus of the
wavelet coefficients is integrated over the desired frequency band [f1 f2]. To integrate
over a frequency band wavelet scales must be changed to frequencies. The time-scale
map (scalogram) must be interpreted in terms of a time-frequency map (spectrogram).
The instantaneous power of the frequency band [f1 f2] is given by
PCWT  t  

1
C

2
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d

2
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2
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f1

W  t , f  / f  df .
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(2.17)

The wavelet equivalent to an averaged periodogram is the global wavelet spectrum and is
given by
W
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n 0
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n

(2.18)

2.6 Nonlinear Analysis
On the basis that HR control may contain nonlinear components, there is an
increasing interest to study HRV using methods other than the standard linear methods,
i.e., time-domain and spectral analysis. These methods are often included under the
umbrella term nonlinear HRV analysis. It has been shown that loss of IBI signal
complexity [50, 89] and loss of fractal like scaling behaviors [90, 91] may be a general
feature of cardiac pathology. Poincaré plot analysis, entropy based measures, and fractal
based measures are but a few HRV analysis techniques used.

2.6.1

Poincaré Plot

The Poincaré plot or first-return map, named after Henry Poincaré, is a plot of IBI
intervals versus the previous IBI interval. Poincare plots are a type of nonlinear analysis
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used to quantify self-similarity [92]. HRV measures based on Poincaré plots are based on
the idea that each IBI is influenced by the previous one [22]. Thus, pairs of successive
IBI form an attractor in the Poincare’ plot. Often an ellipse is fitted to the plotted data
with the long axis along the line of identity defined by y  x . Fig. 8 illustrates the
Poincare’ plot generated using healthy human IBI data. If the center or attractor of the
ellipse is located at the mean IBI ( IBI ), then y   x  2IBI defines the line
perpendicular to the line of identify and passing through the mean [93]. Points above the
line of identity indicate a longer IBI than the preceding IBI, and points below the line of
identity indicate a shorter IBI than the preceding. Standard deviations along the line of
identity (SD2) and perpendicular to the line of identity (SD1) represent the magnitude of
the major and minor axes of the ellipse respectively. SD1 represents the SD of the
instantaneous beat-to-beat variability or short term variability. SD2 represents the SD of
the continuous or long-term variability [92, 94]. In reality the ellipse is primarily a visual
aid and the numerical values of the standard deviations SD1 and SD2 contain the
important data. Also, the ratio of SD1 to SD2 has been suggested to be strongly
associated with mortality in adults with postoperative ischemia [95, 96].
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Fig. 8 – Poincare' Plot using healthy human IBI data.

2.6.2

Sample Entropy

Sample entropy (SampEn) is an embedded entropy that attempts to quantify a signal’s
complexity or rate of new information generation [97]. To understand how sample
entropy is calculated a few definitions follow. Let Xi={x1,…, xi,…xN} represent the
original N-long IBI series. Let um+1[i]={xi,xi+1,…,xi+m} and um[i]= {xi,xi+1,…,xi+m-1}
represent m+1 and m length vectors/sequences taken from X. Also, let the distance d be
the maximum absolute distance between the components of two vectors and is given by
d  u[i], u[ j ]  max  u[i  k ]  u[ j  k ] : 0  k  m  1 .
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For each i ≤ N-m a template vector um[i] is compared to all other m length vectors
um[j] where i ≠ j and j ≤ N-m. The number of j that satisfy d(u[i],u[j]) ≤ r is set as nim .
The unconditional probability of randomly selecting two m length sequences from a
signal that have a distance less than r using the relative frequency methods is
Cim  nim / ( N  m) . Furthermore the averaged probability is given by

 m  r  =  N-m 

1

N m

C
i 1

m
i

(2.19)

Similarly nim1 , Cim1 , and  m1 are calculated for vector lengths of m+1. Finally
sample entropy is determined by
SampEn  m, r , N    ln  m1  r  /  m  r 

(2.20)

Fundamentally, SampEn can be described as the negative logarithm of the conditional
probability of randomly selecting two m-length sequences, from a signal, that have a
distance less than r between them given that they also have a distance less than r if their
lengths are increased to m+1. If SampEn is zero, then consecutive sequences are
identical. Larger values of SampEn represent higher complexity.

2.6.3

Detrended Fluctuation Analysis

Fractal scaling or self-similarity are concepts based on the idea that a system or shape
can be fragmented into smaller parts where each part resembles one another but on
different scales [48]. The Sierpenski triangle is classic example of fractal geometry. A
few examples of fractals occurring in nature include snowflakes, shorelines, crystals, and
some ferns. For the case of IBI, the scale is time. Detrended fluctuation analysis (DFA)
[98] tries to quantify the fractal like or self-similar properties of non-stationary time
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series [99, 100]. “This technique is a modification of root-mean-square analysis of
random walks applied to non-stationary signals” [101]. The root-mean-square fluctuation
of an integrated and detrended time series is measured at different scales and plotted
against the size of the scale onto a log-log plot (see Fig. 9).
First consider an IBI time series of length N. The IBI series is integrated using
k

y  k     IBI  i   IBI 

(2.21)

i 1

where y(k) is the kth value of the integrated series, IBI(i) is the ith interbeat interval, and

IBI is the average interbeat interval for the entire time series. The integrated time series
is then separated into segments of length n. A least squares line is fit to the data in each
segment to define the local trend denoted by yn(k). Next, the integrated time series is
detrended by subtracting the local trend, yn(k) from each segment. Finally, the root-meansquared fluctuation of the integrated and detrended time series is calculated by

F n 

2
1 N
 y  k   yn  k   


N  k 1


(2.22)

where m represents the window or scale size. F(m) is computed on a user defined range
of time scales. The linear relationship between log(F) and log(n) represents the scaling
exponent, α, of the interbeat interval time series. Often two distinct linear regions on the
log-log plot are used to describe the short term scaling, α1, and the long term scaling,
α2[100]. These two regions are separated by a breakpoint located around 12-16 beats
[100]. Fig. 9 shows the DFA plot for a typical human IBI signal with a break point at 12
beats.
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Fig. 9 – Detrended fluctuation analysis using healthy human data. Short term scaling
exponent and long term scaling exponents are represented by α1 and α2. The breakpoint
is located at 12 beats.
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3

Software Design

3.1 Introduction
HRV software packages exist in the form of commercial (HRVLive [102] ),
publically available without source code (Kubios [62]), and open source such as ECGLab
[81, 103], KARDIA[104], and the PhysioToolkit [105] . All these HRV programs offer
useful tools for HRV analysis, but they also have disadvantages. The obvious
disadvantages of commercial packages are the cost, lack of user customization, and
possibly proprietary algorithms, but the advantage is often an active technical support
staff and refined product. Additionally, commercial software typically does not offer
recent or more advanced analysis methods that researchers may want to evaluate.
Software packages that are available to the public without available source code cannot
be customized and often have limited or no technical support. Finally, open source code
packages give the user complete customization, but are often not as refined and easy to
use as commercial software. Many require the knowledge of alternative operating
systems such as Linux, and lower level programming languages. Neither of these
knowledge sets is prevalent with clinicians.
The analysis software HRVAS was developed using MATLAB version 2008b
(Mathworks, Natick, MA). HRVAS contains all needed analysis options and results in a
single graphical user interface (GUI). HRVAS also includes batch processing, a feature
not available in other HRV software packages. HRVAS is open source and un-compiled.
Open source code allows for user updates and customization. Analysis results are
displayed in a tab group to allow for future additional analysis modules and to aid in
keeping all components within a single GUI.
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3.2 Graphical User Interface
The graphical user interface (GUI) consists of three primary components (see Fig.
10). The upper most plot shows the IBI intervals, trend line, and any ectopic intervals.
Double clicking this graph will show both the unprocessed and preprocessed IBI. The
lower left grey area contains all analysis options available to the user. All analysis
options can be saved and reloaded to allow for quick selection of frequently used options.
Any options present in the GUI on exit are saved and reloaded the next time HRVAS is
opened.
The lower right section of Fig. 10 contains analysis results. Each set of results
associated with time-domain, frequency-domain, time-frequency, Poincaré, and nonlinear
analysis are contained in a labeled tab (see Appendix A). The use of tabs allows for
future HRV analysis additions. Double clicking on any of plot will redraw it onto a
separate figure for custom editing and exporting for documents or presentations.
The frequency-domain analysis tab allows for plotting of Welch periodogram, Burg
periodogram, and Lomb-Scargle periodogram. The time-frequency tab allows for
displaying of spectrogram, surface plot, waterfall plot, global power spectrum and
instaneous LF, HF, and LFHF powers. Time-frequency plots can be drawn using
windowed Burg periodogram, windowed LSP, or CWT.
Input data types used by HRVAS are .ibi and .txt files. The expected format of input
files is an ASCII file with one or two columns of data. Two column files must include IBI
time stamps (seconds) in the first column and IBI values (seconds) in the second column.
Files containing only one data column must include only IBI values. Exported analysis
results are saved to a Microsoft Excel® file.
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In an effort to reduce the total files needed for using HRVAS, each major HRV
analysis type, e.g., time-domain, uses only one MATLAB m-file. Similarly, the GUI is
generated using only one MATLAB m-file.

Fig. 10 – HRVAS graphical user interface. The upper most plot is of the IBI intervals and
trend line. The lower left gray area contains all analysis options. The lower right section
contains analyses results.

3.3 HRV Analysis in HRVAS
Fig. 11 represents the analysis process used by HRVAS to compute HRV measures.
The order of preprocessing in HRVAS is ectopic interval detection, ectopic interval
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replacement, and IBI detrending. HRV analysis details were discussed in the previous
chapter.
A batch processing feature allows for unattended analysis of many IBI or RR interval
files. For batch processing all files must be contained within a single directory. At
completion all analysis data is exported to a Microsoft Excel file.
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Fig. 11 – HRV analysis process flowchart.
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CWT

Nonlinear
HRV

3.4 Conclusion
The design of HRVAS provides an easy to use interface in which to compute and
display HRV analysis. Future considerations for improvements include moving all
analysis options to individual tabs, simplifying the export function, and allowing the user
to select which HRV analyses are computed. Not having to perform all HRV analyses
will save processing time and resources. HRVAS will be made available to the public at
http://hrvas.sourceforge.net/ and at the project’s homepage
https://sourceforge.net/projects/hrvas/. HRVAS is distributed free of charge under the
terms of GNU public license so that other users can modify the code and adjust the
program’s performance according to their own requirements.
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4

Software Evaluation

4.1 Introduction
This chapter presents two evaluations that help validate analysis results obtained from
HRVAS. The first evaluation consisted of computing time-domain, frequency-domain
and time-frequency HRV measures based on computer simulated ECG signals. The
second evaluation involved computing all HRV measures using public data from healthy
and congestive heart failure human subjects in an effort to distinguish between groups
and compare to previous work. More specifically, the hypothesis was that CHF causes
reduction in HRV.

4.2 Simulated Data

4.2.1

Methods

4.2.1.1 Data
Computer simulated ECG with IBI were generated to evaluate the reliability of some
HRV measures obtained from HRVAS. The simulation algorithm was implemented in
MATLAB using the ECGSYN model [106]. ECGSYN generates both ECG signals and
locations of all P, Q, R, S, and T waves. R wave locations were used to generate IBI time
series. Three hundred, 30-minute synthetic ECG segments and three hundred, five-minute
synthetic ECG segments were generated with sample rates of 256 Hz. Each segment had
a mean HR of 60 bpm (beats/min) and standard deviation of 1 bpm. The ECG generated
contained oscillations centered at 0.1 and 0.25 Hz to represent the center frequency of
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hypothetical LF and HF contributions respectively. Furthermore, the ratio of LF to HF
power was specified to be 1.0.

4.2.1.2 HRV Analysis
Time-domain, frequency-domain, and time-frequency HRV measures were computed
using HRVAS for comparison with parameters used in generating the synthetic ECG.
Mean IBI, SDNN, mean HR, and SDHR were computed for time-domain HRV measures.
Peak LF, peak HF, nLF, nHF, and LFHF ratios were computed using Welch, Burg, and
Lomb-Scargle periodograms. Peak LF, peak HF, nLF, nHF, and LFHF ratios were also
computed in a time-frequency manner using windowed Burg periodogram, windowed
LSP, and CWT for the 30-minute segments only. Analysis options included: IBI resample
rate (4 Hz), Welch window width (1024 pts.), Welch window overlap (512 pts.), Burg
model order (16), TF window width (300 s), and TF window overlap (150 s). Frequency
bands were specified as 0.04-0.15 Hz for LF and 0.15-0.4 Hz for HF.
Statistical evaluations were performed by inspecting 90% confidence intervals for
both time and frequency-domain measures. LFHF rations were further considered by
performing equivalence test [107]. A confidence interval of indifference was determined
using empirical data from the CARLA study [108]. Confidence intervals of LFHF mean
differences which remain within the interval of indifference are considered to be
indifferent from the expected LHFH value of 1.0.

4.2.2

Results

HRV analysis using HRVAS produced values that closely corresponded with
parameters used for synthetic ECG generation. Results are presented as mean with 90%
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confidence interval (CI). Time-domain HRV values computed for the 5-minute
simulations included: mean IBI, 999.7 (999.7-999.7) ms; SDNN, 16.7 (16.6-16.8) ms;
mean HR, 60.0 (60.0-60.0) bpm; SDHR, 1.0 (1.0 -1.0) bpm. Time-domain HRV values
computed for the 30-minute simulations included: mean IBI, 999.6 (999.6-999.6) ms;
SDNN, 16.6 (16.6-16.6) ms; mean HR, 60.0 (60.0-60.0) bpm; SDHR, 1.0 (1.0-1.0) bpm.
Peak LF and peak HF were 0.10 (0.10-0.10) Hz and 0.25 (0.25-0.25) Hz respectively
for all spectral HRV methods and data lengths. Fig. 12 shows the LF and HF peaks
present in the Lomb-Scargle spectrogram and global power spectrum of a representative
synthetic IBI time series.

Fig. 12 – Lomb-Scargle spectrogram and global PSD for simulated IBI (LFHF=0.5)

Results for nLF and nHF are summarized in Table 1. Results for LFHF ratios are
summarized in Table 2. For 5-minute simulations, the Burg periodogram (0.10-0.26)
produced the most deviation from the expected value of 1.0 and extended beyond the
interval of indifference of -0.2 to 0.2. LSP produced the most accurate LFHF value (0.020.10). For 30-minute simulations, the Burg periodogram (-0.10 to -0.08) produced the
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largest mean difference while the Welch (0.05-0.06) and LS (0.03-0.08) periodograms
produced the least mean difference from expected. All three methods had mean
differences within the interval of indifference determined by equivalence test seen in Fig.
13. Time-Frequency based measures of LFHF for 30-minute simulations showed that the
windowed Burg periodogram (0.02-0.05) produced the largest mean difference from the
expected simulated data. The windowed LSP (0.01-0.04) and CWT (0.02-0.03) produced
LFHF mean differences slightly lower than the windowed Burg method. All three timefrequency methods produced LFHF mean differences within the interval of indifference.

Table 1 – nLF and nHF results of simulated IBI
Duration
5 min.

30 min.

PSD Estimate
Welch
Burg
LS
Welch
Burg
LS
Win. Burg
Win. LS
CWT

nLF (%)

nHF (%)

Mean (90% CI)

Mean (90% CI)

0.51 (0.49-.52)
0.50 (0.49-0.51)
0.50 (0.49-0.50)
0.51 (0.51-0.51)
0.47 (0.46-0.47)
0.51 (0.50-0.51)
0.51 (0.50-0.51)
0.50 (0.50-0.51)
0.51 (0.50-0.51)

0.49 (0.48-0.51)
0.50 (0.49-0.51)
0.50 (0.50-0.51)
0.49 (0.49-0.49)
0.53 (0.53-0.54)
0.49 (0.49-0.50)
0.49 (0.49-0.50)
0.50 (0.49-0.50)
0.49 (0.49-0.50)
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Table 2 –LFHF results of simulated IBI
Duration
5 min.

30 min.

PSD Estimate
Welch
Burg
LS
Welch
Burg
LS
Win. Burg
Win. LS
CWT
Expected/Ideal

LFHF (90% CI)
1.13 (1.08-1.18)
1.18 (1.10-1.26)
1.06 (1.02-1.10)
1.06 (1.05-1.06)
0.90 (0.89-0.92)
1.05 (1.03-1.08)
1.04 (1.02-1.05)
1.03 (1.01-1.04)
1.03 (1.02-1.03)
1.00
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Mean Diff (90% CI)
0.13 (0.08-0.18)
0.18 (0.10-0.26)
0.06 (0.02-0.10)
0.06 (0.05-0.06)
-0.10 (-0.11 - -0.08)
0.05 (0.03-0.08)
0.04 (0.02-0.05)
0.03 (0.01-0.04)
0.03 (0.02-0.03)
0.00

Fig. 13 – LFHF equivalence test. Values are displayed as mean difference with error bars
representing the 90% confidence interval. The grayed area represents the confidence
interval of indifference and is bound by -0.2 to 0.2.

4.2.3

Discussion

Time-domain HRV analysis results for both 5-minute and 30-minute simulations
were indifferent compared to the expected parameters used for simulation. Spectral HRV
measures produced LFHF ratios within the interval of indifference except for the 5minute Burg periodogram. Due to a lower nLF and higher nHF powers, the windowed
Burg periodogram produced a mean LFHF ratio of less than 1.0. The Burg model order
could have played a role in this deviation from expected LFHF ratio.
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4.3 Congestive Heart Failure
5.8 million Americans are living with heart failure with 670,000 new cases and
56,600 deaths annually [109]. Heart failure is a condition in which the heart has a
decreased ability to fill and pump blood to the tissues of the body. In congestive heart
failure (CHF), this decrease causes a backup or congestion of blood in the returning
vessels. Heart failure can result from pathologies such as coronary artery disease,
myocardial infarction, high blood pressure, and cardiomyopathy [110]. As a result of
heart failure, marked changes in autonomic function appear including high sympathetic
activity and reduced vagal-cardiac activity [28]. Studies have shown that HRV associated
with heart failure is reduced compared to healthy [6, 111-113].

4.3.1

Methods

4.3.1.1 Data
To evaluate the viability of HRVAS on real data, HRV analysis was performed on
two public, human datasets taken from the MIT/BIH RR interval database of
physiological signals hosted at Physionet [105]. The MIT/BIH database included beat
annotations of long-term (~24h) ECG recordings that were digitized at 128 samples per
second. Beat annotations, provided in the database, were obtained by automated analysis
with manual review and correction. The healthy/control group (NSR) originally included
54 subjects (30 men, 24 women) aged 24-76 years and having normal sinus rhythm. Two
subjects were excluded due to large numbers of ectopic beats (greater than 2% of total).
The CHF group originally included 29 subjects (8 men, 21 women) aged 34-79 years and
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having congestive heart failure (NYHA classes I, II, or III). Ten subjects were excluded
due to ectopic beat counts exceeding 2% of the total IBI count.

4.3.1.2 HRV Analysis
Physionet annotation files were batch converted to IBI files using a custom shell
script program combined with Physionet’s ann2rr function[105]. HRV analyses were
performed using HRVAS’s batch processing feature. The computer system used for this
project did not provide enough RAM for detrending and HRV analysis of these datasets.
Therefore all HRV analyses were implemented on the High Performance Computing
(HPC) system at the University of Memphis using 4 GB of memory on a single server
node.
IBI preprocessing included ectopic interval detection, ectopic interval removal, and
detrending. Ectopic interval detection was performed using the percent filter (20%) and
standard deviation filter (3 SD). Detrending was accomplished using the wavelet packet
detrending technique with a cutoff frequency of 0.0391 Hz [60]. Frequency bands for
VLF, LF, and HF were 0-0.04 Hz, 0.04-0.15 Hz, and 0.15-0.4 Hz respectively[39]. Only,
LSP based Frequency-domain and time-frequency measures were computed. A complete
list of HRV analysis options used is presented in Table 3.
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Table 3 – HRVAS Analysis Options for NSR/CHF Datasets
Analysis

Parameter (value) or Method

Ectopic Detection

Std. Dev. Filter (3 SD), Percent Filter (20%)

Ectopic Correction

Remove Ectopic

Detrending

Wavelet Packet (cutoff frequency - 0.039 Hz)

Time-Domain

pNNx (50 ms), SDANN (5 min), HRVti and TINN (32 bin
histogram)

Freq.-Domain

VLF (0-0.04 Hz), LF (0.04-0.15 Hz), HF (0.15-0.4 Hz),
Interpolation Rate (2 Hz), Points in PSD (512 pts)

Nonlinear

SampEn (r=0.2 std, m=2), DFA (n=4 to 64 beats, Break Point
=11 beats)

Time-Freq.

Window (300 s), Overlap (150 s)

4.3.1.3 Statistical Analysis
Statistical analyses were performed using SPSS v16 (SPSS, Chicago, IL). Each HRV
statistic was checked for normality by visually inspecting both the histograms and the QQ plots and by considering the Shapiro-Wilk normality test (α=0.05). If both groups
passed the normality test for a given HRV measure, a two-sample, two-tailed t-test
(α=0.05) was used to determine between group significance. Levene’s test (α=0.05) for
equality of variances was used to determine whether to assume equal or unequal
variances. If either group failed normality test, group significance was determined by the
non-parametric Mann-Whitney U test (α=0.05). Some HRV measures were able to be
transformed into normal distributions using a log transform, but this had no effect on
statistical outcomes of any HRV measure. Therefore, only p values using non-parametric
test were reported for any non-normally distributed HRV measure.
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4.3.2

Results

All HRV measures showed a significant difference (p<0.05) between healthy and
CHF subjects except the following: RMSSD, TINN, aTotal, aHF (time-freq.), SD1, and
DFA-α1. Table 4 summarizes the HRV analysis results. Statistics are presented as mean ±
standard deviation for NSR vs. CHF respectively.
All significant time-domain measures were lower for CHF compared to NSR and
included: mean IBI (783.33±78.41 vs. 685.44±84.98 ms), SDNN (29.22±9.36 vs.
21.09±11.53 ms), pNN50 (5.53±5.24 vs. 2.92±2.26 %), SDANN (26.36±8.28 vs.
16.69±7.91 ms), and HRVti (3.07±1.01 vs. 1.80±0.72).
For frequency-domain measures both nLF power (0.73±0.12 vs. 0.6±0.17 ms2) and
LFHF ratio (3.57±2.12 vs. 2.1±1.74) were reduced in CHF. Conversely, aHF power
(0.007±0.006 vs. 0.012±0.009 ms2) and nHF power (0.27±0.12 vs. 0.4±0.17 n.u.) were
significantly higher in CHF. All but one significant time-frequency measure were lower
in CHF compared to NSR and included: aLF power (313.67±211.85 vs. 164.74±207.08
ms2), aTotal power (432.77±277.65 vs. 277.94±333.06 ms2), nLF power (60.84±149.55
vs. 3.04±3.58 %). The nHF power (0.26±0.1 vs. 0.41±0.12 n.u.) obtained by timefrequency analysis was higher in CHF compared to NSR.
Nonlinear HRV analysis showed lower values in CHF obtained by Poincare longterm measure SD2 (194.13±38.99 vs. 95.96±48.14 ms), SampEn (0.78±0.53 vs.
0.53±0.17), and α1 of the DFA plot (1.28±0.18 vs. 0.89±0.24).
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Table 4 – HRV Analysis Results for NSR/CHF Datasets

Measure (units)

Sig.

MeanIBI (ms)
SDNN (ms)
pNN50 (%)
RMSSD (ms)
SDANN (ms)
HRVti
TINN (ms)

***
***
*
ns
***
***
ns

2

aLF (ms )
2

aHF (ms )
2

aTotal (ms )
nLF (n.u.)
nHF (n.u.)
LFHF (%)

Healthy
Mean ± SD
Time Domain
783.33 ± 78.41
29.22 ± 9.36
5.53 ± 5.24
25.70 ± 9.15
26.36 ± 8.28
3.07 ± 1.01
82.93 ± 38.43
Freq. Domain

CHF
Mean ± SD
685.44
21.09
2.92
23.27
16.69
1.80
90.51

±
±
±
±
±
±
±

84.98
11.53
2.66
11.31
7.91
0.72
62.78

ns

0.02 ± 0.01

0.01 ± 0.01

*

0.007 ± 0.006

0.012 ± 0.009

ns
***
***
***

0.02 ± 0.01
0.73 ± 0.12
0.27 ± 0.12
3.57 ± 2.12
Time-Freq

***

313.67 ± 211.85

164.74 ± 207.08

ns

104.67 ± 85.43

81.93 ± 78.76

aTotal (ms )
nLF (n.u.)
nHF (n.u.)
LFHF (%)
rLFHF (%)

**
***
***
***
***

SD1 (ms)
SD2 (ms)
SampEn
DFA-α1
DFA-α2

ns
***
***
***
ns

432.77 ± 277.65
0.74 ± 0.10
0.26 ± 0.10
3.57 ± 1.95
60.84 ± 149.55
Nonlinear
20.07 ± 12.17
194.13 ± 38.99
0.78 ± 0.30
1.28 ± 0.18
1.08 ± 0.11

2

aLF (ms )
2

aHF (ms )
2

ns = not significant,

*

= p<0.05,

**

= p<0.01,
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***

= p<0.005

0.03
0.60
0.40
2.10

±
±
±
±

0.01
0.17
0.17
1.74

277.94
0.59
0.41
1.67
3.04

±
±
±
±
±

333.06
0.12
0.12
0.82
3.58

17.92
95.96
0.53
0.89
1.16

±
±
±
±
±

9.11
48.14
0.17
0.24
0.18

4.3.3

Discussion

HRV analysis results based on time-domain and nonlinear methods followed previous
findings and expectations. As expected, the results of time-domain analysis show an
increase in HR and reduction of HRV in CHF compared to NSR. SD2 from the Poincare’
plot suggest a reduction in long-term variability in the CHF dataset. Similarly, the lower
SampEn values in CHF data suggest lower IBI signal complexity. Values of DFA-α1
obtained for NSR and CHF datasets were similar to values reported by others using these
or similar data [50, 90, 100, 114]. Ho et al. describes the observed group differences in
DFA as a “breakdown of fractal scaling properties” in CHF [114].
Based on the aforementioned reports that CHF produces lower vagal activity and
higher sympathetic activity, one would expect HF powers to be lower and LF powers to
be higher in CHF compared to healthy. However, several studies [114-117] have showed
seemingly contradictory results using spectral based measures as did this research.
Guzzetti et al. (2001) [118] suggest that these observed contradictions can be explained
by the following pathophysiological mechanisms reported in heart failure:


central autonomic regulatory impairment [119]



decreased responsiveness of sympathetic modulation [120]



lower HRV consequent to the stretch of SA node [121]



increased chemoreceptor sensitivity [122].

Finally, although most of the HRV measures show significant difference between
groups, many have substantially overlapping distributions. Thus, any single observation
may will likely fall within the values of overlap and obscure any clinical usefulness.
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4.4 Conclusion
Although, the HRV analysis results comparing NSR and CHF groups presented in
this chapter were not all as expected, the results did accomplish the intended chapter
purposes. These results were in accordance with other studies involving heart failure and
thus provide an encouraging software evaluation. HRV analyses of synthetic data with
user specified parameters were able to extract accurate representations of defined
simulation parameters. Evaluation of HRVAS using both computer-simulated data and
publicly available data helped to demonstrate its precision and value.
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5

Software Application: HRV in Hyperaldosteronism

5.1 Introduction
The adrenal hormone aldosterone has a well-known and important role in regulating
the sodium-potassium balance of the body via renal mechanisms. However, in the past
10-15 years evidence shows that aldosterone also produces non-renal effects particularly
in the cardiovascular system [123]. This newer evidence has helped explain the link of
excess aldosterone (hyperaldosteronism) to maladaptive cardiac remodeling [124, 125].
Cardiovascular diseases such as hypertension, heart failure, and myocardial infarction are
marked with increases of aldosterone levels [123]. Specific aldosterone related changes in
the cardiovascular system include vascular endothelial dysfunction [126], myocardial
fibrosis [126], myocardial apoptosis [127], cardiac hypertrophy [124], and prolonged
ventricular action potentials [124]. Blocking aldosterone using aldosterone antagonist
,e.g., spironolactone and eplerenone, can reduce or halt maladaptive cardiac changes in
animal models [128] and humans [127-129]. Two large trials have further shown that
treatment with aldosterone antagonist reduces mortality and hospitalization in heart
failure patients [130, 131].
Chapter 4 presented evidence that CHF causes changes in HRV, and the previous
paragraph established a connection between hyperaldosteronism and HF. From this
evidence one could hypothesize that a hyperaldosteronism model of HF may produce
changes in HRV similar to CHF. Therefore, we present the following hypotheses based
on an 8-week hyperaldosteronism study:
1. Hyperaldosteronism reduces HRV (treatment effect)
2. Prolonged hyperaldosteronism further reduces HRV (time effect)
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3. The effect of time is different for control and hyperaldosteronism groups
(interaction)

5.2 Methods

5.2.1

Data

One control and one treated dataset, each consisting of 5 male, Sprague-Dawley rats
(Harlan, Indianapolis, IN), were used. The original data collection came from an
unpublished study [132]. Rats were purchased at 3-6 weeks old (100-225 g). Treatment
began when rats were eight weeks old. The hyperaldosteronism treatment group
(ALDOST) included uninephrectomy (left kidney removed), 6 weeks of subcutaneous
aldosterone administration (Fisher Scientific International Inc., Hampton, NH) through
implanted osmotic pumps (Alzet Model 2006, Durect Corporation, Cupertino, CA), and a
salt diet (drinking water containing 1% NaCl and 0.4% KCl). Aldosterone was delivered
continuously at the rate of 0.75 µg/hr. Radio-transmitters (PhysioTel® model CAf40,
Data Sciences International, St. Paul, MN) were implanted in all subjects one week prior
to treatment initiation in order to obtain baseline ECG data. The control group received
only wireless radio-transmitters. ECG was recorded continuously for eight weeks at a
sample rate of 1000 Hz using the Dataquest A.R.T. version 4.0 (Data Sciences
International, St Paul, MN) acquisition system installed on a desktop PC. Seven hours of
ECG data per subject per week were exported from Dataquest A.R.T. to ASCII files.
MATLAB was then used to convert and compress ASCII files to MATLAB binary
format.
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5.2.2

ECG Filtering

ECG filtering was necessary to maximize beat detection efficiency. High-pass
filtering was used to remove baseline wander, and was accomplished by subtracting a low
frequency trend line from the ECG. This trend line was produced by applying a triangular
(two-pass) moving average filter with a window size of 750 points or (0.75 s, cutoff
frequency ~ 0.6 Hz) to the ECG signal. Low-pass filtering to remove high frequency
noise was accomplished using a triangular moving average filter with a window size of 3
points or (0.003 s, cutoff frequency ~ 155 Hz). Moving average filters provided a simple,
effective, and fast method to filter ECG. Combining the two techniques effectively
applied a 0.6-155 Hz bandpass filter to the ECG. The window sizes were primarily
determined via visual inspections and testing with template matching. Frequency cutoffs
were determined by frequency response to unit impulse functions.

5.2.3

ECG Segmentation

ECG segments for HRV analysis were 10 minutes in duration. One segment from
each week of treatment (10 weeks) was extracted to provide longitudinal effects of
aldosterone on HRV. Segments were selected from the middle seven hours occurring
during the rats 12 hour sleep or lights-on cycle. Segments were extracted from the same
day each week.
The process for selecting the 10-minute segment is as follows. A 10 minute moving
window (overlap of 9 minutes) was passed over the entire seven hours of ECG data. ECG
statistics were collected for each window. A list of usable ECG segments was constructed
based on the statistics. Criteria for choosing a usable 10 minute segment included: mean
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HR above 250 beats/min, total number of ectopic beats less than 1% of total beats,
absence of significant missing data, and visual inspection of noise and ectopy. Significant
missing data was defined as having more than 150 consecutive missing data values or
missing more than 150ms consecutively. Segments with less than 150 consecutive
missing data values were interpolated using cubic spline. Finally the usable 10 minute
segment with the lowest HR was chosen for analysis.

5.2.4

QRS Detection

QRS complexes were located using a correlation based template matching algorithm.
Two types of QRS templates were used for template matching. QRS templates were
created by averaging more than 20 QRS complexes. The first type of template was a
global template; global in the sense that one template was suitable for all subjects. Eight
templates were created for each subject (one for each week of treatment) and compared to
each other by computing a correlation coefficient. The template with largest cumulative
correlation was selected for use as the global template. In general, approximately 95% of
cases, the global template was used for template matching. The second type of template
was a self-template. When global templates failed to yield satisfactory results for a
particular week of data and resulted in large numbers of missed QRS complexes, a selftemplate was generated based on the current ECG data. Both types of templates were 161
samples in length to encompass the entire rat PQRST cardiac cycle.
A sliding window was passed across the ECG signal, and a correlation coefficient
was computed between the template and the ECG contained within each window of equal
length. This process produced a new data series containing correlation coefficients rxy.
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The correlation coefficient between two N length segments of ECG x and y was
computed using the following equation:

  x  n   x   y  n   y 
N

rxy 

n 1

N

2 N

  x  n   x    y  n   y 
n 1

.

(2.23)

2

n 1

Computational speed of template matching was improved using three methods. The
first method involved reducing the number of times the sliding window translated across
the signal. By translating every third ECG sample instead of indexing one sample, 1/3 as
many correlation coefficients were computed. Skipped rxy values were replaced using
cubic spline interpolation. The second method involved parallelizing a portion of the
template matching code for multi-core processor environments and implemented on a
laptop (Intel Core Duo T2300 @ 1.66 GHz, 2 GB DDR2). The third method combined
both the skip indexing and parallelized methods. Skipping samples, parallelizing code,
and a combination of the two methods reduced computation time (17.2 s original) by
approximately 64% (6.2 s), 58% (7.3 s), and 82% (3.16 s) respectively. These data are
based on the results of 3 simulations of each technique using an ECG segment of 600,000
samples and a template of 161 samples in length.
If the correlation between template and ECG segment exceeded a defined threshold
value a detection flag was set to high. This flag was held in a high state until rxy dropped
below a defined lower threshold (see Fig. 14). High and low thresholds were set to 0.35
and 0.4 respectively and were determined by personal judgment based on trial and error
testing. A QRS complex was set as the largest rxy peak between any high and low
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detection flag switches. This double threshold method helps eliminate multiple peak
detections within a close vicinity of one another.
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Fig. 14 – QRS detection using template matching. Plots include (a) example template
used for QRS detection by template matching, (b) rat ECG with detected QRS
complexes, (c) rxy data series and peaks detected using the double threshold technique,
and (d) state of the detection flag used in the double threshold technique.

5.2.5

HRV Analysis

Twenty-seven HRV measures were used based on the recommended procedures in
the literature. Time-domain HRV measures considered included mean IBI, mean HR,
pNN10, SDNN, SDNNi, HRVti, and TINN. LF and HF power in absolute and
normalized units were considered for both frequency-domain and time-frequency
analysis. To quantify sympatho-vagal balance LFHF was considered using both
frequency-domain and time-frequency analysis. Similarly, the global sympatho-vagal
equilibrium was computed using the rLFHF measure. Finally, nonlinear HRV analysis
included DFA-α1, DFA-α1, SD1, SD2, and SampEn. Table 5 summarizes options used for
HRV analysis.
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Table 5 – HRVAS Analysis Options for Hyperaldosteronism Datasets
Analysis

Parameter (value) or Method

Ectopic Detection

Std. Dev. (3), percent (20%)

Ectopic Correction

Remove ectopic

Detrending

Smoothness Priors (155)

Time-Domain

pNNx (10 ms), SDNNi (0.5 min), HRVti and TINN (32 bins)

Freq.-Domain

VLF (0-0.16 Hz), LF (0.16-0.6 Hz), HF (0.6-3 Hz),
Interpolation Rate (10 Hz), Points in PSD (512 pts)

Nonlinear

SampEn (r=0.5 std, m=2) [133], DFA (n=4 to 64, Break Point
=10)
Window (30 s), Overlap (15 s)

Time-Freq.

5.2.6

Statistical Analysis

In order to check the previously stated hypotheses, several statistical techniques were
used. Descriptive statistics were firstly provided for each variable concerning the HRV
for both control and treated groups. As the factors in this study are time and treatment, a
two-factor repeated measures ANOVA was used to test the main effects of each factor on
HRV measures in addition to possible interaction effects. The assumption of sphericity
was checked by Mauchly’s test of sphericity. When the sphericity assumption was
violated, epsilon measures were compared to the value 0.75. If epsilon values were under
the level of 0.75, the Greenhouse-Geisser method was used to compute the F statistic.
Otherwise F statistic was computed by the Huynh-Feldt method. Post hoc tests were also
performed when the main effects were significant. For the case of significance of
interaction, a one-factor, repeated measure ANOVA was done. In this special case, the p-
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values are compared with the value 0.05 divided by 2 or 0.025. Statistical analysis was
performed using SPSS v16 (SPSS, Chicago, IL).

5.3 Results
Results of HRV analysis are summarized in Table 6. The following statistics are
presented as mean ± standard deviation for control vs. ALDOST respectively. ANOVA
results indicated significant differences in the treatment factor between the control and
ALDOST group for mean HR (298.9±12.3 vs. 324.4±35.3). The main effect of time was
found to be significantly different for the following HRV measures: mean IBI (187.6
±22.4 vs. 202.0 ±15.3), mean HR (298.9 ±21.7 vs. 324.4 ±35.3), RMSSD (3.2 ±1.3 vs.
3.7 ±1.7), SDNN (2.3 ±0.9 vs. 2.6 ±1.1), and SD1 (2.3 ±0.9 vs. 2.6 ±1.2). Similarly, there
were significant interactions (time*treatment) found for mean IBI, mean HR and
RMSSD.
Mean IBI, mean HR, and RMSSD were further analyzed by one-factor repeated
measures ANOVA because of significant interaction between time and treatment. The
effect of time was significant (α=0.025) on mean IBI in both controls (p=0.002) and
ALDOST (p=0.001) groups. The effect of time was also significant on mean HR in both
controls (p=0.002) and ALDOST (p=0.006) groups. Finally, the effect of time was not
significant on RMSSD in controls (p=0.146) but was significant in ALDOST (p=0.005).
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Table 6 – HRV Anaylsis Results for Hyperaldosteronism Datasets
pwithin

pbetween

Measure (units) Time Time*Treat Treatment
MeanIBI (ms) ***
MeanHR (bpm) ***
pNN10 (%)
ns
RMSSD (ms)
*
SDNN (ms)
*
SDANN (ms)
ns
HRVti
ns
TINN (ms)
ns
aLF (ms 2 )

***
***
ns
**
ns
ns
ns
ns

Control

Aldo

Mean ± SD

Mean ± SD

Time Domain
ns
202.02
*
298.91
ns
1.38
ns
3.18
ns
2.31
ns
2.17
ns
7.72
ns
6.30
Freq. Domain

±
±
±
±
±
±
±
±

15.28
21.72
2.80
1.25
0.93
0.86
2.97
2.95

187.62
324.35
2.39
3.70
2.58
2.44
7.32
6.34

±
±
±
±
±
±
±
±

22.39
35.31
4.95
1.72
1.14
1.04
2.38
2.90

ns

ns

ns

0.03 ± 0.03

0.02 ± 0.02

ns

ns

ns

0.15 ± 0.07

0.13 ± 0.06

aTotal (ms )
nLF (n.u.)
nHF (n.u.)
LFHF (ratio)

ns
ns
ns
ns

ns
ns
ns
ns

0.19
0.17
0.83
0.23

0.16
0.14
0.86
0.18

aLF (ms 2 )

ns

ns

ns

2.52 ± 2.83

2.74 ± 3.07

ns

ns

ns

10.53 ± 8.90

14.95 ± 15.44

aTotal (ms )
nLF (n.u.)
nHF (n.u.)
LFHF (ratio)
rLFHF ratio)

ns
ns
ns
ns
ns

ns
ns
ns
ns
ns

SD1 (ms)
SD2 (ms)
SampEn
DFA-α1
DFA-α2

**
ns
ns
ns
ns

ns
ns
ns
ns
ns

ns = not significant,

*

2

aHF (ms )
2

2

aHF (ms )
2

= p<0.05,

**

ns
ns
ns
ns
Time-Freq

±
±
±
±

0.09
0.10
0.10
0.18

ns
13.85 ± 11.94
ns
0.18 ± 0.10
ns
0.82 ± 0.10
ns
0.24 ± 0.17
ns
0.03 ± 0.08
Nonlinear
ns
2.26 ± 0.88
ns
8.02 ± 3.28
ns
1.89 ± 0.45
ns
0.68 ± 0.20
ns
1.35 ± 0.16
= p<0.01,

***
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= p<0.005

±
±
±
±

0.07
0.07
0.07
0.12

18.50
0.15
0.85
0.19
0.01

±
±
±
±
±

18.89
0.06
0.06
0.09
0.01

2.62
9.61
1.76
0.64
1.39

±
±
±
±
±

1.22
3.21
0.44
0.16
0.12

5.4 Discussion
The majority of HRV measures showed no significant differences between treatment
groups, effect of time, or their interaction. The five measures (mean IBI, mean HR,
RMSSD, SDNN, and SD1) that did show significance could be questioned because of
overlapping standard deviations, abrupt shifts in measured variability, (see Appendix B)
and/or consideration of study limitations. First, the mean value of all five significant
HRV measures obtained at week eight of aldosterone treatment has a relatively large
deviation from the previous weeks (see Appendix B). Mean IBI, SDNN, RMSSD, and
SD1 abruptly deflects to higher values while mean HR deflects to lower values. For mean
IBI and mean HR this deviation could be explained if an exponential response to
treatment was expected. Also, an increasing and decreasing linear time response to
control treatments can be observed in both mean IBI and mean HR measures respectively
(see Appendix B). However, control conditions were expected to produce no significant
changes with respect to time.
Other factors and limitations are likely responsible for the unexpected significances in
HRV. The foremost limitation to consider was the small sample size. Another limitation
was the method used for choosing a single 10-minute IBI interval from 7 hours of ECG
data. As discussed before, segments were chosen based on HR and ectopic interval
criteria. The segment of lowest HR was assumed to be the segment of least movement
and was chosen to keep the level of activity between subjects as constant as possible.
This was a suggestion made by other HRV authors [134]. Ideally all ECG would be
recorded during controlled and repeatable environmental and physiological conditions,
but the available data were from previous work. Alternatively, one could segment ECG
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using activity levels or EEG sleep stages as discussed below. Again, neither of these
parameters was available.
Another limitation that may have contributed to the unexpected significances was the
inability to control for effects of sleep stages on HRV. Others have shown that, in
humans, the sleep stage determined via EEG can affect HRV [135-139]. Because no EEG
data were present, a possible solution could be to perform HRV analysis on 12 or 24
hours of IBI in an effort to average out any effect of sleep cycles. Using such long data
series increase the probability of non-stationarities. However, time-frequency and certain
nonlinear HRV analysis methods obviate non-stationarities. During this stage of the
study, the computing resources to perform HRV analysis on 12 or 24 hours of rat IBI data
were not available.
Physiological changes seen from a rat hyperaldosteronism model are possibly not
significant enough to elucidate the reduction of HRV seen in complete CHF of humans.
If HRV changes exist in CHF populations but not in the hyperaldosteronism rat model,
then the HRV changes seen in human CHF may be primarily due to neural related
changes and not cardiac remodeling. The hyperaldosteronism studies consider
cardiovascular changes and little if any neural change. As noted in Chapter 1.2
cardiovascular performance and neural control are closely interlinked.
There also exists the possibility that “variability” is altered in the presented model but
not detectable using the current methods. Let us assume that physiological changes do
exist in the rat hyperaldosteronism model and that these changes do affect variability
within the heart firing sequences. Perhaps the changes in variability, calculated using the
current methods, are lost due to condensing of all cardiac events into a single time point
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(the R-wave). Any changes in sub-beat variability such as the PR, QRS, or QT interval
may be lost by only considering RR interval variability.
Finally, as with most animal models of human pathophysiology, there can be
concerns of comparing two different species and whether the model is representative.
Some authors consider the physiological origins or meanings of HRV in rats to be similar
to that in humans [67] but with varying working parameters. For instance, the oscillations
seen in spectral based HRV measures, e.g. RSA and Mayer, are present in both rat and
human but centered at differing frequencies. No one has yet to verify the significance of
most HRV measures, particularly nonlinear measures, between species.

5.5 Conclusion
The rat hyperaldosteronism model of HF in the study was generally unable to
reproduce the changes in HRV expected based on other HF studies. Given that
improvements are made to the protocol and/or more research is done to improve the
understanding of HRV in rats compared to humans, the model could prove useful in
future HRV research.
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6

Summary and Conclusions
HRVAS provides researchers an easy to use graphical user interface, several formats

for importing data, batch processing, and tools for exporting. Analysis features of
HRVAS include IBI preprocessing, time-domain, frequency-domain, time-frequency, and
nonlinear HRV analysis. Researchers also have the ability to completely customize the
source code to suit their personal preferences or study needs. These usability and analysis
features are all useful in studying HRV.
Software evaluations of HRVAS using simulated data and public CHF data helped to
demonstrate its accuracy and worth as a HRV analysis tool. Application of HRVAS to
study HRV in rat hyperaldosteronism models further displayed value of its use as a viable
HRV analysis tool for researchers and future interdepartmental research.
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Appendix A – HRVAS Analysis Modules

Fig. 15 – Analysis Options Module
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Fig. 16 – Time-domain Analysis Module

Fig. 17 – Frequency-domain Analysis Module
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Fig. 18 – Poincaré Analysis Module

Fig. 19 – Nonlinear Analysis Module
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Fig. 20 – Time-frequency Analysis Module
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Appendix B – Additional Statistics

Table 7 – Test of Within-Subjects Contrast for mean IBI
Treatment

Fit

Sig

Control

Linear

0.001

Quadratic

0.694

Cubic

0.457

Order 4

0.079

Linear

0.000

Quadratic

0.008

Cubic

0.059

Order 4

0.018

Aldost

Table 8 – Tests of Within-Subjects Contrast for mean HR
Treatment

Fit

Sig

Control

Linear

0.000

Quadratic

0.670

Cubic

0.476

Order 4

0.066

Linear

0.001

Quadratic

0.018

Cubic

0.086

Order 4

0.021

Aldost
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Table 9 – Tests of Within-Subjects Contrast for RMSSD
Treatment

Fit

Sig

Control

Linear

0.076

Quadratic

0.208

Cubic

0.517

Order 4

0.666

Linear

0.372

Quadratic

0.049

Cubic

0.023

Order 4

0.129

Aldost

Table 10 – Tests of Within-Subjects Contrast for SDNN
Treatment

Fit

Sig

Control

Linear

0.062

Quadratic

0.235

Cubic

0.657

Order 4

0.677

Linear

0.397

Quadratic

0.062

Cubic

0.019

Order 4

0.251

Aldost
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Table 11 – Tests of Within-Subjects Contrast for SD1
Treatment

Fit

Sig

Control

Linear

0.082

Quadratic

0.185

Cubic

0.512

Order 4

0.687

Linear

0.392

Quadratic

0.048

Cubic

0.021

Order 4

0.128

Aldost
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Fig. 21 – Distribution of mean IBI by treatment time and treatments group
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Fig. 22 – Distribution of mean HR by treatment time and treatments group

Fig. 23 – Distribution of RMSSD by treatment time and treatments group
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Fig. 24 – Distribution of SDNN by treatment time and treatments group
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Fig. 25 – Distribution of SD1 by treatment time and treatments group
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